抄録
Fundamental and clinical studies were carried out for evaluating the usefulness of Cefuroxime axetil (CXM-AX) in the treatment of periodonitis, pericoronitis or osteitis of the jaw. The results are summarized below.
1. At 60-120 minutes after oral administration of CXM-AX 250mg, CXM levels in the cyst, the gum and the alveolar bone tissues were 1.64μg/g (mean of 8 samples), 1.24μg/g (1 sample) and 0.24μg/g (1 sample), respectively, and ratio of tissue levels to serum levels were 66.4, 58.2 and 8.6%, respectively. At 90-135 minutes after the administration of CXM-AX 500mg, mean CXM levels in the cyst, the gum and the alveolar bone were 1.07μg/g (3 samples), 1.63μg/g (3 samples) and 0.7μg/g (2 samples), respectively, and ratio of tissue levels to serum levels were 22.2, 26.5 and 29.1%, respectively.
2. In the clinical evaluation, 28 patients receved orally either 250mg or 500mg of CXM-AX three times daily. Both in assessment based on scores and in physician's assessment, the efficacy rate in the total cases was 89.3%. The efficacy rates were 86.4% in 22 cases in the 750mg administration group, and 100%, in 6 cases in the 1500mg administration group.
3. Bacteriological examination was performed in 17 strains isolated from 11 out of 28 patients. CXM, at the concentration of 0.78μg/ml or lower, inhibited the growth of every isolate.
4. As for adverse events, only mild nausea and vomitting were observed in one patient out of the 28 (3.6%) .
From the above, CXM-AX is considered to be highly useful in the treatment of oral surgical infections.
